MétaCan
Menu
Back to cohort
Record W4392699445 · doi:10.1016/j.jaci.2024.01.031

Activated sputum eosinophils associated with exacerbations in children on mepolizumab

2024· article· en· W4392699445 on OpenAlexfundno aff
Gabriella E. Wilson, James Knight, Qing Liu, Ashish Shelar, Emma Stewart, Xiaomei Wang, Xiting Yan, Joshua Sanders, Cynthia M. Visness, Michelle A. Gill, Rebecca S. Gruchalla, Andrew H. Liu, Meyer Kattan, Gurjit K. Khurana Hershey, Alkis Togias, Patrice M. Becker, Matthew C. Altman, William W. Busse, Daniel J. Jackson, Ruth R. Montgomery, Geoffrey Chupp

Bibliographic record

VenueJournal of Allergy and Clinical Immunology · 2024
Typearticle
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsnot available
FundersNational Center for Advancing Translational SciencesU.S. National Library of MedicineNational Institute of Allergy and Infectious DiseasesPfizerNational Heart, Lung, and Blood InstituteNational Institutes of HealthSierra OncologyRegeneron PharmaceuticalsTeva Pharmaceutical IndustriesSanofiGenentechAstraZenecaAmgenGlaxoSmithKline
KeywordsMepolizumabSputumMedicineAsthma exacerbationsImmunologyEosinophilAsthmaPathologyTuberculosis

Abstract

fetched live from OpenAlex

Background MUPPITS-2 was a randomized, placebo-controlled clinical trial that demonstrated mepolizumab (anti-IL-5) reduced exacerbations and blood and airway eosinophils in urban children with severe eosinophilic asthma. Despite this reduction in eosinophilia, exacerbation risk persisted in certain patients treated with mepolizumab. This raises the possibility that subpopulations of airway eosinophils exist that contribute to breakthrough exacerbations. Objective We aimed to determine the effect of mepolizumab on airway eosinophils in childhood asthma. Methods Sputum samples were obtained from 53 MUPPITS-2 participants. Airway eosinophils were characterized using mass cytometry and grouped into subpopulations using unsupervised clustering analyses of 38 surface and intracellular markers. Differences in frequency and immunophenotype of sputum eosinophil subpopulations were assessed based on treatment arm and frequency of exacerbations. Results Median sputum eosinophils were significantly lower among participants treated with mepolizumab compared with placebo (58% lower, 0.35% difference [95% CI 0.01, 0.74], P = .04). Clustering analysis identified 3 subpopulations of sputum eosinophils with varied expression of CD62L. CD62L int and CD62L hi eosinophils exhibited significantly elevated activation marker and eosinophil peroxidase expression, respectively. In mepolizumab-treated participants, CD62L int and CD62L hi eosinophils were more abundant in participants who experienced exacerbations than in those who did not (100% higher for CD62L int , 0.04% difference [95% CI 0.0, 0.13], P = .04; 93% higher for CD62L hi , 0.21% difference [95% CI 0.0, 0.77], P = .04). Conclusions Children with eosinophilic asthma treated with mepolizumab had significantly lower sputum eosinophils. However, CD62L int and CD62L hi eosinophils were significantly elevated in children on mepolizumab who had exacerbations, suggesting that eosinophil subpopulations exist that contribute to exacerbations despite anti-IL-5 treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.318
Teacher spread0.300 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations33
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Allergy and Clinical ImmunologySame topicAsthma and respiratory diseasesFrench-language works237,207